RECIST 1.1 compared with RECIST 1.0 in patients with advanced renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy.

Krajewski, Katherine M; Nishino, Mizuki; Ramaiya, Nikhil H; Choueiri, Toni K

Krajewski, Katherine M; Nishino, Mizuki; Ramaiya, Nikhil H; Choueiri, Toni K.

Affiliation

Krajewski KM; 1 Department of Imaging, Dana-Farber Cancer Institute, and Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, 450 Brookline Ave, Boston, MA 02115.

AJR Am J Roentgenol ; 204(3): W282-8, 2015 Mar.

Article in En | MEDLINE | ID: mdl-25714313

Subject(s)

Carcinoma, Renal Cell/drug therapy; Kidney Neoplasms/drug therapy; Vascular Endothelial Growth Factor A/therapeutic use; Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell/pathology; Female; Humans; Kidney Neoplasms/pathology; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Treatment Outcome

Key words

CT; Response Evaluation Criteria in Solid Tumors (RECIST); renal cell carcinoma; tumor response assessment; vascular endothelial growth factortargeted therapy

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Renal Cell / Vascular Endothelial Growth Factor A / Kidney Neoplasms Type of study: Evaluation_studies / Observational_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: AJR Am J Roentgenol Year: 2015 Type: Article

Fulltext

XML

PubMed Links

Search on Google